 Nektar Therapeutics NASDAQ: NKTR is trading significantly lower Monday morning after the companys Phase 3 PIVOT trial, in combination with Bristol-Myers Squibb Co NYSE: BMY, did not meet its primary endpoint. Following a review of the study for efficacy and safety by an. 